Tulun Saylan on Muck Rack

Tulun Saylan

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tulun

Contact Tulun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial

|
By Ignacio Melero, Tamara Tanos, Emiliano Calvo Aller, Camilla Qvortrup, Marloes van Dongen, Iosune Baraibar, Seung-Hoon Beom, Fiona Thistlethwaite, Maria Garcia, Maria García, María García, Victoria Woodcock, Pablo Umaña, Christine McIntyre, Lining Chen, Christian Heichinger, Heather Hinton, Tulun Saylan, Iakov I Davydov, Ernesto Guarin, Axel Boehnke, Victor Moreno
| Nature Verified
Abstract We evaluated cibisatamab, a carcinoembryonic antigen (CEA)-directed CD3 T cell-engaging bispecific antibody, in combination with FAP-4-1BBL, a fibroblast activation protein (FAP)-targeted 4-1BB ligand providing tumor-localized co-stimulation, in an open-label phase 1b dose-escalation study in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing after two or more prior therapies.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified